Column

2025.04.25

We would like to share with you our latest data obtained using the CDAHFD (Choline-Deficient, High-Fat Diet) mouse model, which rapidly reproduces key features of MASH, including steatosis, inflammation, and fibrosis. In this study, we evaluated the GLP-1 receptor agonist Liraglutide, and observed a clear anti-fibrotic effect in this model.   Overview of the CDAHFD Model Induced by a…

READ MORE

2025.04.18

We will introduce the obese MASH model in this article.   Existing MASH (metabolic dysfunction-associated steatohepatitis) models have different characteristics, such as obese/non-obese type, presence/absence of dyslipidemia, and differences regarding the capability to progression to HCC. Since MASH is a complex disease with diverse ways of pathogenesis, it is important to evaluate your test substance in multiple…

READ MORE

2025.04.11

In this article, we will introduce the key points for selecting a model that will lead to the success of your PSC research.   Ideal features of a PSC model:   ・Duct injury (intra- and extrahepatic) ・Ductular reaction ・Onion-like periductal fibrosis ・Portal inflammation ・Association with IBD             ▼ ▼ ▼  …

READ MORE

2025.04.04

A recent study using the STAM™ mouse model demonstrates clear efficacy in MASH progression inhibition – this could support your preclinical strategy.   ▶ Publication: Reactive Dicarbonyl Scavenging with 2-Hydroxybenzylamine Improves MASH   In this paper, the authors highlight the effect of 2-HOBA, a scavenger of reactive dicarbonyl electrophiles (DE), in improving MASH by reducing…

READ MORE

2025.03.28

Today, we are excited to share a recent study highlighting a promising approach to targeting G protein-coupled receptors (GPCRs) in NASH/MASH treatment.This study addresses a long-standing challenge in the development of NASH/MASH therapeutics using GPCR-targeting compounds. GPR119 activation has been shown to promote GLP-1 secretion and glucose-responsive insulin secretion, making it a compelling target for…

READ MORE

2025.03.21

Today, we would like to introduce our experience of the bleomycin-induced IPF study.   One of our most requested models, apart from our proprietary MASH model, is the bleomycin-induced IPF model for evaluations of drugs against lung fibrosis.   In the past 10 years, we have conducted over 150 studies using the bleomycin-induced IPF model and…

READ MORE

2025.03.14

In this article, we introduce our COPD model.   Why Choose Our COPD Model? ✅Clinically Relevant Evaluations: Our model includes in-life CT scans, lung function tests (FVC via flexiVent, SpO₂ by pulse oximetry), and histological analysis, closely mirroring clinical studies. ✅ Multiple Analyses from a Single Subject: We provide comprehensive assessments, including histology, gene expression,…

READ MORE

2025.03.07

We are pleased to share with you the latest material introducing our CCl4 model, which should provide valuable insights for your preclinical research.   You can download the summary version here. (This version includes an overview and some model data)   The Full version includes the following content. ・Comparison table of human and CCl4 model ・Target and modality information…

READ MORE

2025.02.27

We are pleased to introduce the latest materials showcasing our lung disease models, designed to provide valuable insights for your pre-clinical research.   You can download the digest version here: (This version includes an overview of the models and detailed information on selected models.)   If you are interested in accessing the complete version (12…

READ MORE

2025.02.21

We are pleased to share with you the latest material introducing our BDL model, which should provide valuable insights for your preclinical research.   You can download the summary version here. (This version includes an overview and some model data)   The Full version includes the following content. ・Comparison table of human and BDL model…

READ MORE